Literature DB >> 14648716

Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma.

Justin Stebbing1, Brian Gazzard, Tom Newsom-Davis, Mark Nelson, Steve Patterson, Frances Gotch, Sundhiya Mandalia, Mark Bower.   

Abstract

Infection with HIV-1 is known to impair B cell function. To further elucidate the role of B cells during infection and tumorigenesis, we studied their numbers in cases of AIDS-related Kaposi's sarcoma (KS) during the HAART era. Patients with AIDS-related KS were identified from a database of 4,480 HIV-1 positive individuals and the incidence of KS and rate ratio was stratified according to nadir number of B cells, measured as the CD19 count. In an unadjusted model, we observed that lower B cell counts were associated with a statistically significant increased risk of KS development (p < 0.001). We also observed a trend toward increased counts during KS resolution. When adjusted for nadir CD4 count in a multi-variable model, higher B cell counts were protective against KS development (p = 0.015). These data highlight a potential role for B cells and therefore the humoral immune system in KS aetiopathogenesis. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14648716     DOI: 10.1002/ijc.11601

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality.

Authors:  J Stebbing; M Bower; S Mandalia; M Nelson; B Gazzard
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

2.  Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.

Authors:  Alastair B Law; Gail Ryan; Stephen Lade; H Miles Prince
Journal:  Int J Hematol       Date:  2010-02-10       Impact factor: 2.490

Review 3.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

4.  Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Denise Whitby; Victoria Wang; Stefania Pittaluga; Deirdre O'Mahony; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

5.  Pathology of rituximab-induced Kaposi sarcoma flare.

Authors:  Liron Pantanowitz; Klaus Früh; Sharon Marconi; Ashlee V Moses; Bruce J Dezube
Journal:  BMC Clin Pathol       Date:  2008-07-23

6.  Castleman disease.

Authors:  Ibrahiem Saeed-Abdul-Rahman; Ali M Al-Amri
Journal:  Korean J Hematol       Date:  2012-09-25

7.  Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma.

Authors:  Emilien Billon; Anne-Marie Stoppa; Lena Mescam; Massimo Bocci; Audrey Monneur; Delphine Perrot; François Bertucci
Journal:  Clin Sarcoma Res       Date:  2018-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.